Advanced Search
Contact | Corporate | Help

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Sponsors:
  • Memorial Sloan-Kettering Cancer Center
  • Amgen
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Breast Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Female
Names:
  • Drug: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
Enrollment:
70

Additional information about NCT00591851.


SourceSolution © 2008-2012